100% agree. Excellent analysis. My sentiments are the same, great product but poor execution and poor communication. Too many PRs touting possibilities and none of them coming to fruition. Trial enrollment, progress and results are not communicated well either. Hopefully we will have some good accurate news soon. If not those poor folks that bought at 3+ range are going to be left holding the bag of those millions of shares that were recently sold from warrants exercised at .~70...